Tamer I Khayal sold $6.9M of TMDX
Chief Commercial Officer at TransMedics Group, Inc.. 63,260 shares at an average of $108.54, traded May 1, 2024, filed May 14, 2024.
Score components
- +15RoleOfficer
- +25Trade size$6.9M at market
- +20Share of holdings soldSold 87% of holdings
- +15Cluster7 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +8.3%, 3m +22.3%, 6m -31.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-059829, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -14,854 | $106.25 | $1.6M | 58,198 | May 14, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -11,789 | $107.20 | $1.3M | 46,409 | May 14, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1,792 | $108.35 | $194k | 44,617 | May 14, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -13,078 | $109.68 | $1.4M | 31,539 | May 14, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -5,313 | $110.00 | $584k | 26,226 | May 14, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -100 | $113.16 | $11k | 26,126 | May 14, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -326 | $116.80 | $38k | 25,800 | May 14, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -759 | $117.97 | $90k | 25,041 | May 14, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1,417 | $119.00 | $169k | 23,624 | May 14, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1,815 | $119.96 | $218k | 21,809 | May 14, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -422 | $121.21 | $51k | 21,387 | May 14, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -444 | $121.84 | $54k | 20,943 | May 14, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -100 | $123.66 | $12k | 20,843 | May 14, 2024 |
| May 1, 2024 | SOpen-market sale Common Stockindirect: By the Tamer Ibrahim Ahmed Khayal Trust10b5-1 | -11,051 | $105.71 | $1.2M | 0 | May 14, 2024 |
Related signals
Other insiders at TransMedics Group, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | TMDXbuy TransMedics Group, Inc. | David Weill director | $109k 1,336 shares | +9% | |
| 31Weak | TMDXsell TransMedics Group, Inc. | Thomas James Gunderson director | $722k 9,624 shares | -37% | |
| 52Moderate | TransMedics Group, Inc. | Stephanie Lovell director | $178k 1,193 shares | -29% | |
| 38Weak | TransMedics Group, Inc. | David Weill director | $524k 3,571 shares | -23% | |
| 46Moderate | TransMedics Group, Inc. | Nicholas Corcoran See remarks | $413k 2,966 shares | -9% | |
| 67Notable | TransMedics Group, Inc. | Gerardo Hernandez Chief Financial Officer | $1.1M 7,611 shares | -51% | |
| 40Moderate | TransMedics Group, Inc. | Anil P. Ranganath See remarks | $120k 864 shares | -6% | |
| 48Moderate | TransMedics Group, Inc. | Gerardo Hernandez Chief Financial Officer | $128k 920 shares | -6% | |
| 46Moderate | TransMedics Group, Inc. | David Weill director | $693k 5,000 shares | -29% | |
| 37Weak | TransMedics Group, Inc. | Anil P. Ranganath See remarks | $436k 3,000 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.